These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 27939096)

  • 1. Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
    Decaup E; Rochotte J; Pyronnet S; Bousquet C; Jean C
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):246-248. PubMed ID: 27939096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
    Begum A; Ewachiw T; Jung C; Huang A; Norberg KJ; Marchionni L; McMillan R; Penchev V; Rajeshkumar NV; Maitra A; Wood L; Wang C; Wolfgang C; DeJesus-Acosta A; Laheru D; Shapiro IM; Padval M; Pachter JA; Weaver DT; Rasheed ZA; Matsui W
    PLoS One; 2017; 12(7):e0180181. PubMed ID: 28692661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma.
    Scianò F; Terrana F; Pecoraro C; Parrino B; Cascioferro S; Diana P; Giovannetti E; Carbone D
    Future Med Chem; 2024 Feb; 16(3):271-289. PubMed ID: 38269431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
    Roy-Luzarraga M; Reynolds LE; de Luxán-Delgado B; Maiques O; Wisniewski L; Newport E; Rajeeve V; Drake RJG; Gómez-Escudero J; Richards FM; Weller C; Dormann C; Meng YM; Vermeulen PB; Saur D; Sanz-Moreno V; Wong PP; Géraud C; Cutillas PR; Hodivala-Dilke K
    Cancer Res; 2022 May; 82(10):1909-1925. PubMed ID: 35350066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
    Le Large TYS; Bijlsma MF; El Hassouni B; Mantini G; Lagerweij T; Henneman AA; Funel N; Kok B; Pham TV; de Haas R; Morelli L; Knol JC; Piersma SR; Kazemier G; van Laarhoven HWM; Giovannetti E; Jimenez CR
    J Exp Clin Cancer Res; 2021 Mar; 40(1):91. PubMed ID: 33750427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.
    Canel M; Sławińska AD; Lonergan DW; Kallor AA; Upstill-Goddard R; Davidson C; von Kriegsheim A; Biankin AV; Byron A; Alfaro J; Serrels A
    Gut; 2023 Dec; 73(1):131-155. PubMed ID: 36977556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
    Osipov A; Blair AB; Liberto J; Wang J; Li K; Herbst B; Xu Y; Li S; Niu N; Rashid R; Ding D; Liu Y; Wang Z; Wolfgang CL; Burkhart RA; Laheru D; Zheng L
    Cancer Biol Med; 2021 Feb; 18(1):206-214. PubMed ID: 33628595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.
    Lander VE; Belle JI; Kingston NL; Herndon JM; Hogg GD; Liu X; Kang LI; Knolhoff BL; Bogner SJ; Baer JM; Zuo C; Borcherding NC; Lander DP; Mpoy C; Scott J; Zahner M; Rogers BE; Schwarz JK; Kim H; DeNardo DG
    Cancer Discov; 2022 Dec; 12(12):2774-2799. PubMed ID: 36165893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy.
    Blair AB; Wang J; Davelaar J; Baker A; Li K; Niu N; Wang J; Shao Y; Funes V; Li P; Pachter JA; Maneval DC; Dezem F; Plummer J; Chan KS; Gong J; Hendifar AE; Pandol SJ; Burkhart R; Zhang Y; Zheng L; Osipov A
    Gastroenterology; 2022 Nov; 163(5):1267-1280.e7. PubMed ID: 35718227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy.
    Murphy KJ; Zhu J; Trpceski M; Pereira BA; Timpson P; Herrmann D
    Biochem Soc Trans; 2022 Aug; 50(4):1129-1141. PubMed ID: 35929603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
    Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
    Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer.
    Li Z; Mo F; Guo K; Ren S; Wang Y; Chen Y; Schwartz PB; Richmond N; Liu F; Ronnekleiv-Kelly SM; Hu Q
    Med; 2024 Apr; 5(4):348-367.e7. PubMed ID: 38521069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FAK and paxillin, two potential targets in pancreatic cancer.
    Kanteti R; Batra SK; Lennon FE; Salgia R
    Oncotarget; 2016 May; 7(21):31586-601. PubMed ID: 26980710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FAK activity in cancer-associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer.
    Zaghdoudi S; Decaup E; Belhabib I; Samain R; Cassant-Sourdy S; Rochotte J; Brunel A; Schlaepfer D; Cros J; Neuzillet C; Strehaiano M; Alard A; Tomasini R; Rajeeve V; Perraud A; Mathonnet M; Pearce OM; Martineau Y; Pyronnet S; Bousquet C; Jean C
    EMBO Mol Med; 2020 Nov; 12(11):e12010. PubMed ID: 33025708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
    Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
    Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma.
    Zhou H; Wang W; Cai Z; Jia ZY; Li YY; He W; Li C; Zhang BL
    J Nanobiotechnology; 2024 Jun; 22(1):353. PubMed ID: 38902759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer.
    Davidson C; Taggart D; Sims AH; Lonergan DW; Canel M; Serrels A
    Br J Cancer; 2022 Nov; 127(10):1893-1905. PubMed ID: 36138073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.
    Gomez-Chou SB; Swidnicka-Siergiejko AK; Badi N; Chavez-Tomar M; Lesinski GB; Bekaii-Saab T; Farren MR; Mace TA; Schmidt C; Liu Y; Deng D; Hwang RF; Zhou L; Moore T; Chatterjee D; Wang H; Leng X; Arlinghaus RB; Logsdon CD; Cruz-Monserrate Z
    Cancer Res; 2017 May; 77(10):2647-2660. PubMed ID: 28249896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.